 Under Bresch 's leadership , Mylan made several acquisitions , including a $ 1 @.@ 6 billion acquisition of Agila Specialties . A $ 5 @.@ 3 billion acquisition of Abbott Laboratories was announced in conjunction with plans to re @-@ organize the company in the Netherlands and move its domicile to a country with lower taxes . The New York Times said there was something " disconcerting " about a company that benefits from large government contracts renouncing their citizenship for tax benefits , but Mylan would eventually save almost 10 percent of its revenues in taxes each year . Bresch said it was a difficult choice to make , but it had to be done to maintain competitiveness against pharmaceutical manufacturers that had already executed similar inversion strategies . 
